<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
The European Commission (EC) has granted conditional marketing approval for Bristol Myers Squibb & Co’s (NYSE: BMY) Abecma (idecabtagene vicleucel, ide-cel) for relapsed and refractory multiple myeloma. Abecma is a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.
...read full article on Benzinga
